[Anticoagulative effect and antiplatelet aggregation effect of combination of Hirudo and Tabanus on rat model of blood stasis syndrome].
OBJECTIVE
To observe anticoagulative effect and antiplatelet aggregation effect of the combination of Hirudo and Tabanus with different dose-ratio on rat model of blood stasis syndrome.


METHODS
The rat model of blood stasis syndrome was established by subcutaneous injection of adrenaline combined with stimulation of icy water. Then prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB) contents and inhibition rate of blood platelet aggregation were determined.


RESULTS
Platelet aggregation increases, APTT and PT reduced, and FIB contents increased in model control group significantly (P<0.001). Hirudo, Tabanus and the combination of Hirudo and Tabanus had antiplatelet aggregation effect in varying degrees. APTT and PT were prolonged significantly (P<0.05 and P<0.01, respectively) in Hirudo group, Tabanus group and combination groups, especially in the group with dose-ratio of Hirudo to Tabanus being 4:3. FIB contents decreased significantly in combination group with dose-ratio being 3:1 (P<0.05).


CONCLUSIONS
The combination groups of Hirudo and Tabanus have better effect of anticoagulation and antiplatelet aggregation than Hirudo group and Tabanus group. While in the four combination groups, the group recommended by classical TCM monograph with dose-ratio of Hirudo to Tabanus being 4:3, has the best anticoagulation effect.
Liang
Jin-quan
JQ
Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou 510405, China. ljq@adr.com.cn
Mi
Sui-qing
SQ
Wang
Ning-sheng
NS
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects*; D001778:Blood Coagulation Disorders / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D004175:Diptera; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004837:Epinephrine / Q000008:administration & dosage; D047709:Hirudo medicinalis; D008297:Male; D008419:Materia Medica / Q000008:administration & dosage / Q000494:pharmacology*; D010314:Partial Thromboplastin Time; D010974:Platelet Aggregation / Q000187:drug effects*; D011517:Prothrombin Time; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
D008419:Materia Medica; D004837:Epinephrine